Hemab Therapeutics (COAG) investor relations material

Company overview and business model

• Clinical-stage biotech focused on innovative therapies for blood coagulation disorders, targeting serious bleeding and thrombotic diseases across global markets.

• Lead assets include sutacimig (HMB-001) for Glanzmann thrombasthenia and Factor VII deficiency, and HMB-002 for Von Willebrand Disease, both in advanced clinical development.

• Strategic roadmap aims for 2 commercial medicines, 2 late-stage, and 2 early-stage clinical programs by 2030.

• Maintains global economic development and commercialization rights for all assets.

• Patient-centric approach with deep domain expertise and flexible clinical trial design.

Financial performance and metrics

• No product revenue to date; operations funded by $346M in private placements and convertible debt.

• Net losses of $48.7M (2024) and $63.9M (2025); accumulated deficit of $181.9M as of December 31, 2025.

• Research and development expenses rose from $41.4M (2024) to $59.6M (2025), driven by clinical advancement and increased headcount.

• Cash, cash equivalents, and marketable securities of $185.5M as of December 31, 2025.

• IPO expected to raise $231.4M (or $267M if underwriters' option exercised) at $17/share midpoint.

Use of proceeds and capital allocation

• Proceeds to fund clinical development of sutacimig and HMB-002, additional discovery/preclinical activities, and general corporate purposes.

• Expected to fund operations into 2029, but not sufficient for regulatory approval of any product candidate.

• May use a portion for potential acquisitions of complementary companies, products, or technologies.